TFRC and glioma: As thoroughly elucidated by Fan et al. in 2018, the HFn can cross the BBB with TfR1-mediated RMT mechanism, and the HFn-encapsulated DOX significantly reduce the glioma tumor burden and improve the median survival times [18].